Analyst David Lebowitz works at CITI and is focused on the Healthcare sector with 353 price targets and ratings documented since 2016 spanning on 17 stocks. Analyst's average stock valuation to be materialised ratio is 69.99% with an average time for price targets to be met of 155.06 days.
Most recent stock forecast was given on ASND, Ascendis Pharma A/S at 03-Nov-2022.
David Lebowitz best performing recommendations are on SNDX (SYNDAX PHARMACEUTICALS, INC).
The best stock recommendation documented was for SNDX (SYNDAX PHARMACEUTICALS, INC) at 3/11/2020. The price target of $10 was fulfilled within 1 day with a profit of $1.79 (15.18%) receiving and performance score of 151.82.
Average potential price target upside